Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: CNS tumours

286MO - Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma


10 Sep 2022


Mini Oral session: CNS tumours


Radiological Imaging;  Immunotherapy

Tumour Site

Central Nervous System Malignancies


Maximilian Mair


Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047


M.J. Mair1, J. Leitner2, M. Zvonek3, H. Windhager1, K. Häller1, G.J. Kührer2, C. Paiato1, B. Kiesel4, A. Wöhrer5, G. Widhalm4, K. Nenning3, G. Langs3, M. Preusser1, J. Furtner2, A.S.S. Berghoff1

Author affiliations

  • 1 Department Of Medicine I, Division Of Oncology And Christian Doppler Laboratory For Personalized Immunotherapy, Medical University of Vienna, 1090 - Vienna/AT
  • 2 Department Of Biomedical Imaging And Image-guided Therapy, Division Of Neuroradiology And Musculoskeletal Radiology, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Department Of Biomedical Imaging And Image-guided Therapy, Computational Imaging Research Lab, Medical University of Vienna, 1090 - Vienna/AT
  • 4 Department Of Neurosurgery, Medical University of Vienna, 1090 - Vienna/AT
  • 5 Department Of Neurology, Division Of Neuropathology And Neurochemistry, Medical University of Vienna, 1090 - Vienna/AT


Login to access the resources on OncologyPRO.

Abstract 286MO


In glioblastoma, the benefit of immunotherapy is limited to a small, yet to be defined subgroup. Due to the immunological diversity and as tissue availability remains a challenge, clinically practicable biomarkers are urgently needed.


Patients treated for newly diagnosed isocitrate dehydrogenase (IDH)-wildtype glioblastoma were included. Tumor-infiltrating lymphocytes (TILs) were analyzed by immunohistochemistry for CD3, CD8 and PD-1 and quantified using tissue phenomics software. Extraction of quantitative radiomics parameters was performed using PyRadiomics on preprocessed preoperative MRI images of (A) contrast-enhancing tumor tissue and (B) T2-hyperintense signal abnormalities as a surrogate for non-enhancing tumor tissue and perifocal edema. TIL parameters were predicted by ElasticNet models, and correlations between predicted and quantified values were used to evaluate prediction accuracy.


In total, 133 patients (39.1% female, median age 62 (range: 20-80) years) were included. O6-methylguanine-methyltransferase (MGMT) promoter methylation status was known in 96 tumors, of whom 42 (43.8%) were methylated. Median percentages of TILs based on total cells were 0.95% (range: 0.08%-5.47%) for CD3+, 0.40% (0.05%-2.78%) for CD8+, and 0.19% (0.02%-0.84%) for PD1+ cells. Median densities were 73.0 cells/mm2 (3.1-450.7) for CD3+, 28.0 cells/mm2 (5.2-104.4) for CD8+, and 13.2 cells/mm2 (1.6-61.4) for PD1+ TILs. In the contrast-enhancing tumor region, PD-1+ TIL densities which were predicted based on radiomics parameters correlated with actual values (r = 0.444, p < 0.001). In contrast, there was no predictive value of radiomic features for CD3+ and CD8+ TIL densities or percentages in contrast-enhancing tumor tissue (r < 0.2, p > 0.05). However, in non-enhancing T2-hyperintense tissue, a weak predictive power for the absolute number of CD3+ (r = 0.315, p = 0.003) and CD8+ (r = 0.274, p = 0.017) TILs was detected.


These provisional results may serve as a proof of concept for further investigations on “immuno-radiomic” parameters as possible immune biomarkers in brain tumors. Validation of these results in an independent cohort is ongoing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Austrian Federal Ministry for Digital and Economic Affairs; National Foundation for Research, Technology and Development; Christian Doppler Research Association.


M.J. Mair: Financial Interests, Personal, Other: Pierre Fabre. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, Glaxo Smith Kline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer-Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, Glaxo Smith Kline, AbbVie; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair: EORTC; Non-Financial Interests, Leadership Role, EANO President: EANO. A.S.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.